An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis
Start Date
6/29/2026
Completion Date
12/31/2030
Summary
The purpose of this study is to evaluate the disease-drug-drug interaction (DDDI) potential of afimkibart (also known as RO7790121). This will be assessed by the characterization of the pharmacokinetics (PK) of cytochrome P450 (CYP) enzyme substrates alone and after administration of afimkibart in participants with moderately to severely active ulcerative colitis (UC).
Eligibility Criteria
Age Range: 18 years to 60 years
Interventions
Afimkibart
Caffeine
Warfarin
Omeprazole
Dextromethorphan
Midazolam
Vitamin K
Conditions
Locations
Erick H. Alayo Medical Corporation - Gastro SB Clinic
Chula Vista, California 91910
United States
Allied Biomedical Research Institute, Inc
Miami, Florida 33155
United States
Gastro Health Research
Miami, Florida 33176-2416
United States
UZ Leuven Gasthuisberg
Leuven, 3000
Belgium
AZ Delta (Campus Rumbeke)
Roeselare, 8800
Belgium
Charite Research Organisation GmbH
Berlin, 10117
Germany
Centrum Medyczne "Medis"
Bydgoszcz, 85-229
Poland
Amicare Sp. z o.o. S.K.
Lodz, 91-495
Poland
Medrise sp z o.o
Lublin, 20-582
Poland
Allmedica Badania Kliniczne Sp z o.o. Sp K.
Nowy Targ, 34-400
Poland
NZOZ Eskulap Pabianice
Pabianice, 92-500
Poland
SOLUMED Centrum Medyczne
Późna, 60-529
Poland
Centralny Szpital Kliniczny MSW w Warszawie
Warsaw, 02-507
Poland
WIP Warsaw IBD Point Profesor Kierkus
Warsaw, 04-501
Poland
PlanetMed sp. z o.o.
Wroc?aw, 52-210
Poland
Royal Liverpool University Hospital
Liverpool, L7 8XP
United Kingdom
University College London Hospitals
London, W1T 7HA
United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, NE1 4LP
United Kingdom